Previous 10 |
The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event. For further details see: Tango Therapeutics (TNGX) Investor Presentation - Slideshow
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participa...
- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discover...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participa...
Tango Therapeutics (NASDAQ:TNGX): Q3 GAAP EPS of -$0.28. Revenue of $6.79M Press Release For further details see: Tango Therapeutics reports Q3 results
- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 - - On track for IND filing in fourth quarter of 2021 for TNG908, an MTA- cooperative PRMT5 inhibitor that is synthetic lethal with MTAP deletion, for mult...
Tango Therapeutics (NASDAQ:TNGX) has appointed Marc Rudoltz as the company’s new Chief Medical Officer. An alumnus of the Massachusetts Institute of Technology (MIT) and SUNY-Upstate Medical University, Rudoltz has over 20 years of experience in leading clinical-stage drug develop...
Posting the third consecutive weekly loss, the healthcare stocks in the S&P 500 fell ~0.4% over the week. While healthcare became the fourth worst performing sector, the broader index edged ~0.5% higher during the week. Among healthcare stocks with more than $300M market cap and...
News, Short Squeeze, Breakout and More Instantly...
Tango Therapeutics Inc. Company Name:
TNGX Stock Symbol:
NASDAQ Market:
2024-06-25 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present...